MYFEMBREE: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Estradiol/norethisterone acetate/relugolix (Primary)
- Indications Pregnancy complications
- Focus Adverse reactions
- Sponsors Myovant Sciences; Sumitomo Pharma; Sumitomo Pharma America
Most Recent Events
- 10 Nov 2023 Planned initiation date changed from 1 Jun 2023 to 1 Jan 2025.
- 27 Mar 2023 Planned initiation date changed from 1 Feb 2023 to 1 Jun 2023.
- 27 Feb 2023 New trial record